- Home
- SUPX vs PBYI Comparison
SUPX vs PBYI Comparison
Compare SUPX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPX | PBYI |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | Singapore | United States |
| Employees | 40 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 336.4M | 343.9M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | SUPX | PBYI |
|---|---|---|
| Price | $8.02 | $7.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 388.8K | 263.1K |
| Earning Date | 05-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.61 | $2.75 |
| 52 Week High | $76.00 | $7.90 |
Technical Indicators
Market Signals| Indicator | SUPX | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 58.03 |
| Support Level | $6.76 | $5.75 |
| Resistance Level | $10.92 | $7.25 |
| Average True Range (ATR) | 1.11 | 0.34 |
| MACD | 0.26 | 0.07 |
| Stochastic Oscillator | 43.03 | 64.79 |
Price Performance
Historical ComparisonAbout SUPX Super X AI Technology Limited Ordinary Shares
Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.